Get the Stockscreener App
0.70
0.00%
0.00
After Hours:
.70
InspireMD Inc. stock is traded at $0.70, with a volume of 52,672.
It is up +0.00% in the last 24 hours and down -23.93% over the past month.
InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of coronary and vascular diseases. The company offers CGuard carotid embolic prevention systems for use in carotid artery applications; and MGuard prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions. It is also developing NGuard, a neurovascular flow diverter that diverts blood flow away from cerebral aneurysms in order to seal the aneurysms. InspireMD, Inc. distributes its products in Europe, Latin America, the Middle East, and Asia. The company is headquartered in Tel Aviv, Israel.
See More
Previous Close:
$0.70
Open:
$0.71
24h Volume:
52,672
Relative Volume:
0.72
Market Cap:
$32.79M
Revenue:
$10.85M
Net Income/Loss:
$-51.31M
P/E Ratio:
-0.9498
EPS:
-0.737
Net Cash Flow:
$-40.15M
1W Performance:
-8.78%
1M Performance:
-23.93%
6M Performance:
-60.45%
1Y Performance:
-70.46%
1-Day Range:
$0.6901
$0.71
1-Week Range:
$0.6901
$0.8199
52-Week Range:
$0.63
$2.565
InspireMD Inc. Stock (NSPR) Company Profile
Name
InspireMD Inc.
Sector
Industry
Phone
972 3 6917691
Address
4 Menorat Hamaor Street, Tel Aviv
Compare NSPR vs ABT, MDT, SYK, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NSPR
InspireMD Inc.
|
0.70 | 32.79M | 10.85M | -51.31M | -40.15M | -0.737 |
ABT
Abbott Laboratories
|
101.29 | 175.27B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
88.64 | 113.38B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
272.36 | 104.47B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
43.92 | 63.65B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.29 | 49.74B | 6.30B | 1.07B | 1.09B | 1.8406 |
InspireMD Inc. Stock (NSPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-02-26 | Initiated | Maxim Group | Buy |
| Jan-07-16 | Initiated | Rodman & Renshaw | Buy |
| Mar-13-15 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-26-13 | Initiated | Oppenheimer | Outperform |
InspireMD Inc. Stock (NSPR) Latest News
Form 4 InspireMD Inc For: 27 September By Investing.com - Investing.com UK
Form 4 InspireMD Inc For: 26 September By Investing.com - Investing.com Nigeria
Director Stuka Paul reports acquiring and disposing of two warrant series at InspireMD (NSPR). - Stock Titan
InspireMD (NSPR) director Gary S. Roubin acquired and disposed of warrants with different exercise prices. - Stock Titan
InspireMD (NSPR) director Michael Berman reports acquiring and disposing of warrants at two exercise prices. - Stock Titan
InspireMD amends certain Series J, Series K warrants - Medical Buyer
InspireMD (NASDAQ: NSPR) Revises Series J and K Warrants with $0.7674 Exercise Price and FDA-Linked Expiry by May 2028 - Kalkine Media
InspireMD Amends Warrants for Up to $11 Million Tied to FDA Approval - Minichart
InspireMD amends warrants tied to FDA approval timeline By Investing.com - Investing.com South Africa
InspireMD Amends Warrants to Support CGuard Prime Launch - TipRanks
InspireMD amends warrants tied to FDA approval timeline - Investing.com
InspireMD Announces Amendments to Certain Series J and Series K Warrants, Providing Potential Gross Proceeds of Up to $11 Million - manilatimes.net
An anticipated FDA approval could open up $11 million for InspireMD's stroke-prevention device. - Stock Titan
InspireMD Q2FY26 Results: Net loss widens to $14.3M on recall impact - scanx.trade
Full Transcript: InspireMD Q2 2026 Earnings Call - Benzinga
InspireMD announces inducement grants - Medical Buyer
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - manilatimes.net
Inspiremd Stock Price Forecast. Should You Buy NSPR? - StockInvest.us
InspireMD Inc. (NSPR) Key Financial Ratios – Valuation, Profitability & More - Value Research
InspireMD to Participate in Upcoming H.C. Wainwright 28th Annual Global Investment Conference - The Manila Times
InspireMD Inc. (NSPR) Peer Comparison – Compare with Others - valueresearchonline.com
InspireMD Inc. Series B Warrants (NSPRZ) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
InspireMD Inc (NSPR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
InspireMD Inc. Series B Warrants (NSPRZ) Peer Comparison – Compare with Others - Value Research
InspireMD Earnings Call: Recall Pain, Regulatory Potential - TipRanks
InspireMD Inc. Series B Warrants (NSPRZ) Key Financial Ratios – Valuation, Profitability & More - Value Research
InspireMD Inc. (NSPR) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
InspireMD (NSPR) Drops 4.65% to $0.89 as Key Support at $0.85 Comes into FocusETF Creation Redemption - siam.in
Maxim Group Maintains InspireMD(NSPR.US) With Buy Rating, Maintains Target Price $3 - Moomoo
InspireMD (NSPR) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
InspireMD Q2 2026 Earnings: Revenue Misses $1.77 Million Estimate - Sci-Tech Today
Maxim Group Maintains InspireMD(NSPR.US) With Buy Rating, Cuts Target Price to $3 - Moomoo
NSPR Rallies After Hours On FDA Green Light for Key Stroke-Prevention Trial Despite Withdrawn Annual Guidance - Stocktwits
Lake Street Maintains InspireMD(NSPR.US) With Buy Rating, Maintains Target Price $4 - Moomoo
InspireMD total revenue down 0.4% to USD 1,771,000 in Q2 2026 - Medical Buyer
Form 8K InspireMD Inc For: 17 August By Investing.com - Investing.com South Africa
InspireMD Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
InspireMD Q2 revenue holds at $1.8 million - grafa.com
InspireMD Releases Q2 2026 Financial Results - AlphaStreet
InspireMD, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Earnings call transcript: InspireMD Q2 2026 revenue miss weighs on shares - Investing.com Nigeria
InspireMD Inc reports results for the quarter ended June 30Earnings Summary - TradingView
symbol__ Stock Quote Price and Forecast - CNN
InspireMD reports Q2 2026 revenue $1.77M, net loss $14.3M; cash & marketable securities $30.4M - TradingView
InspireMD Reports $1.77 Million Q2 Revenue and $14.32 Million Net Loss - Quiver Quantitative
InspireMD (NSPR) recall turns U.S. sales negative — and deepens quarterly loss - Stock Titan
InspireMD Q2 Operating Expenses USD 13.671 Mi - Moomoo
InspireMD Reports Second Quarter 2026 Financial Results - manilatimes.net
InspireMD (NSPR) Surges 16.97% to $0.98, Pushing Toward Key ResistanceSentiment Shift - vinanet.vn
InspireMD, Inc. (NSPR) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
INSPIREMD Q2 2026 Earnings Preview: Recent $NSPR Insider Trading, Hedge Fund Activity, and More - Moomoo
InspireMD Inc. Stock (NSPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.51%
0.97%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):